This week in Drug Discovery (28 September – 2 October 2026)
News round-up for 28 September – 2 October 2026 by Megan Thomas, Content Team at DDW.
This week’s news roundup covers the upcoming the Drug Discovery Innovators & Investors Conference in London, as well as global updates on cancer research.
The top stories:
In-person event: Drug Discovery Innovators & Investors panel covers UK regulation
The Drug Discovery Innovators & Investors (DDII) UK Conference has announced a new panel, From Rules to Runway: How UK Regulation Can Accelerate or Obstruct Drug Development, examining how organisations can navigate the UK regulatory environment while supporting innovation and accelerating the development of new therapies.
Can vitamin C improve outcomes in people with pre-cancer blood disorders?
Results of an investigators’ Phase II clinical trial in vitamin C have been published by Wiley online in Cancer, a peer-reviewed journal of the American Cancer Society.
Melbourne radiopharmaceuticals spinout launches with AUD$12 million
Australian radiopharmaceuticals spinout, Skopos Bio, has launched with an AUD$12 million (US$8.3 million) seed round, led by a global investor syndicate.
GSK to acquire potential asset for multiple myeloma
GSK has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter Phase I trials in 2027.
$1 million Stephenson Global Prize honours pioneering KRAS research
Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research.